Form 4: Maravai LifeSciences Director John DeFord Acquires 17,500 Shares

Director John DeFord of Maravai LifeSciences Holdings, Inc. purchased 17,500 shares of Class A Common Stock at an average price of $5.75.

Summary

• John DeFord, a director at Maravai LifeSciences Holdings, Inc., acquired 17,500 shares of Class A Common Stock on November 12, 2024.
• The shares were purchased at a weighted average price of $5.75 per share.
• The purchase was made in multiple transactions with prices ranging from $5.72 to $5.78 per share.
• Following the transaction, Mr. DeFord directly owns 70,046 shares of the company's Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying can be a positive signal, but this is a routine transaction and not a large amount relative to the company's market cap.

Positives

• The purchase of shares by a director can be seen as a positive sign of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who trade their company's stock. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The purchase by a director is a common occurrence and is not unusual in the context of corporate governance.

Stakeholder Impact

• The purchase may have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Maravai LifeSciences, MRVI, John DeFord, insider trading, share purchase, Class A Common Stock, director